Zeta HBME-2 Antibody. Zeta’s mouse monoclonal antibody recognizes HBME-1 and is a monoclonal antibody and recognizes an unknown antigen present in normal tracheal epithelium, microvilli of mesothelioma cells, and adenocarcinoma of breast, lung, and pancreas. The HBME-1 antibody was first described by Battifora et al. in 1992. HBME-1 shows greater immunostaining with malignant lesions than benign lesions with a membranous or luminal pattern of staining.
Hector Battifora mesothelial-1 (HBME-1) is an anti-mesothelial monoclonal antibody that recognizes an unknown antigen on microvilli of mesothelioma cells. The HBME-1 antibody stains normal mesothelial cells as well as epithelial mesotheliomas in a thick membrane pattern. The HBME-1 antibody also reacts with some (20-30%) carcinomas showing cytoplasmic immunostaining.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.